Heron Therapeutics Inc Receivables Turnover Ratio (HRTX), from the second quarter 2026 to the second quarter 2025 current and historic results, rankings and more - CSIMarket
CSIMarket
 


Heron Therapeutics Inc   (NASDAQ: HRTX)
 

Heron Therapeutics Inc Accounts Receivables Turnover Ratio from the second quarter 2026 to the second quarter 2025

Quarterly Results, Trends, Rankings, Statistics


Heron Therapeutics Inc 's ability to collect accounts receivable sequentially worsen to 1.76, pointing to a challenging and on top of that deteriorating business climate for the Major Pharmaceutical Preparations industry. Heron Therapeutics Inc 's Accounts Receivable average collection period in the Jun 30 2026 quarter, has increased to 207 days, from 203 days, in the Mar 31 2026 quarter.

If we take a look into Healthcare sector 518 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Jun 30 2026 from 1587 to 3378.

What is Receivable Turnover Ratio?
What is Heron Therapeutics Inc Selling?


What is Receivable Turnover Ratio?





HRTX Receivables Turnover Ratio (Jun 30 2026)
II. Quarter
(Mar 31 2026)
I. Quarter
(Dec 31 2025)
IV. Quarter
(Sep 30 2025)
III. Quarter
(Jun 30 2025)
II. Quarter
Y / Y Receivable Change 12.06 % 6.3 % 13.57 % 20.9 % 8.44 %
Y / Y Revenue Change 3.64 % -11.37 % 2.2 % 15.29 % 2.36 %
Receivable Turnover Ratio (TTM) 1.76 1.8 1.88 1.93 1.95
HRTX's Total Ranking # 3378 # 1587 # 1501 # 514 # 1475
Accounts Receivable average collection period days 207 203 194 189 187
Seq. Receivable Change 7.02 % -6.58 % 10.54 % 1.4 % 1.52 %
Seq. Revenue Change 10.55 % -19.77 % 13.86 % 2.63 % -5.47 %


Receivable Turnover Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 170
Healthcare Sector # 519
Overall Market # 3378

Receivable Turnover Ratio Statistics
High Average Low
2.83 2.02 1.22
(Sep 30 2020)   (Mar 31 2018)






Financial Statements
Heron Therapeutics Inc 's Accounts Receivable $ 90 Millions Visit HRTX's Balance sheet
Heron Therapeutics Inc 's Sales TTM $ 152 Millions Visit HRTX's Income Statement
Sources of HRTX's Revenues Visit HRTX's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
HRTX's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
HRTX's Growth Rates HRTX's Roa HRTX's Inventory Turnover Ratio HRTX's Dividend Comparisons
HRTX's Profitability Ratios HRTX's Roi HRTX's Asset Turnover Ratio HRTX's Dividend Growth
HRTX's Valuation Ratios HRTX's Roe HRTX's Financial Strength Ratios HRTX's Dividend Payout Ratio



Companies with similar Receivables Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector Receivable Turnover Ratio Revenues for 12 Months ending Jun 30 2026 Receivable at quarter ending Jun 30 2026
Kewaunee Scientific Corporation  4.63 $ 275.985  Millions$ 59.584  Millions
Orasure Technologies Inc  4.62 $ 111.978  Millions$ 24.227  Millions
Bristol myers Squibb Company  4.60 $ 49,186.000  Millions$ 10,689.250  Millions
Omniab Inc   4.60 $ 38.457  Millions$ 8.363  Millions
Yunhong Green Cti Ltd   4.58 $ 20.662  Millions$ 4.513  Millions
Orthopediatrics Corp  4.56 $ 251.278  Millions$ 55.123  Millions
Cryo cell International Inc   4.54 $ 31.128  Millions$ 6.851  Millions
Aligos Therapeutics Inc   4.54 $ 31.518  Millions$ 6.945  Millions
Bioventus Inc   4.49 $ 581.106  Millions$ 129.410  Millions
Fulgent Genetics Inc   4.45 $ 322.973  Millions$ 72.541  Millions
Gyre Therapeutics Inc   4.43 $ 119.383  Millions$ 26.928  Millions
Qt Imaging Holdings Inc exact Name Of Registrant As Specified In Its Charter _______________________  4.42 $ 25.185  Millions$ 5.695  Millions
Supernus Pharmaceuticals inc   4.41 $ 830.438  Millions$ 188.224  Millions
Eli Lilly And Company  4.40 $ 79,665.800  Millions$ 18,094.850  Millions
Neurocrine Biosciences Inc   4.40 $ 3,373.900  Millions$ 767.475  Millions
Lantheus Holdings Inc   4.39 $ 1,555.343  Millions$ 354.642  Millions
Waters Corporation  4.38 $ 4,644.249  Millions$ 1,059.341  Millions
Organon and Co   4.31 $ 6,139.000  Millions$ 1,422.750  Millions
Vsee Health Inc   4.30 $ 10.759  Millions$ 2.500  Millions
Alkermes Plc   4.30 $ 1,667.652  Millions$ 388.132  Millions
Glaukos Corp  4.29 $ 500.031  Millions$ 116.471  Millions
Dexcom Inc   4.25 $ 4,968.800  Millions$ 1,168.000  Millions
Vericel Corporation  4.18 $ 306.303  Millions$ 73.289  Millions
Retractable Technologies Inc  4.14 $ 33.488  Millions$ 8.087  Millions
Apyx Medical Corp  4.14 $ 58.105  Millions$ 14.035  Millions
Regenxbio Inc   4.13 $ 174.482  Millions$ 42.238  Millions
Revvity Inc  4.12 $ 2,911.811  Millions$ 706.371  Millions
Pro dex Inc   4.12 $ 77.548  Millions$ 18.836  Millions
Stoke Therapeutics Inc   4.12 $ 27.588  Millions$ 6.704  Millions
Medinotec Inc   4.08 $ 10.247  Millions$ 2.513  Millions

Date modified: 2026-10-05T11:03:41+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.